Human coagulation factor VIII concentrate

European Pharmacopoeia (EP) Reference Standard

CAS Number:
Pricing and availability is not currently available.


pharmaceutical primary standard




certificate is enclosed in each package

mfr. no.


Featured Industry

Pharmaceutical (small molecule)



General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.


Unit quantity: 40 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference subtance catalogue.


Other Notes

Sales restrictions may apply.

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
F8 gene and phenotype: single player in a team?
Anna Pavlova
Blood, 121(19), 3784-3785 (2013-05-11)
S V Ignat'ev et al.
Klinicheskaia laboratornaia diagnostika, (3)(3), 20-22 (2013-07-03)
The sample consisted of 102 patients with hemophilia infected and non-infected with hepatitis viruses. It is established that in case of inhibitory form of hemophilia concentration of IgG increases at the expense of subclass II and in case of non-inhibitory...
Gouri Shankar Pandey et al.
BioMed research international, 2013, 793502-793502 (2013-04-05)
Flow cytometry is widely used in cancer research for diagnosis, detection of minimal residual disease, as well as immune monitoring and profiling following immunotherapy. Detection of specific host proteins for diagnosis predominantly uses quantitative PCR and western blotting assays. In...
Factor VIII products and inhibitors in severe hemophilia A.
Alfonso Iorio et al.
The New England journal of medicine, 368(15), 1456-1456 (2013-04-12)
Samantha C Gouw et al.
Blood, 121(20), 4046-4055 (2013-04-05)
The objective of this study was to examine the association of the intensity of treatment, ranging from high-dose intensive factor VIII (FVIII) treatment to prophylactic treatment, with the inhibitor incidence among previously untreated patients with severe hemophilia A. This cohort...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.